DMAC - DiaMedica Therapeutics Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 574.48M
Enterprise Value 346.28M
Trailing P/E N/A
Forward P/E 1N/A
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)
Price/Book (mrq)6.52
Enterprise Value/Revenue 3N/A
Enterprise Value/EBITDA 6-4.38

Trading Information

Stock Price History

Beta (5Y Monthly) 1.92
52-Week Change 347.79%
S&P500 52-Week Change 321.03%
52 Week High 35.93
52 Week Low 31.70
50-Day Moving Average 34.48
200-Day Moving Average 33.32

Share Statistics

Avg Vol (3 month) 348.96k
Avg Vol (10 day) 364.53k
Shares Outstanding 514.13M
Float 9.56M
% Held by Insiders 113.06%
% Held by Institutions 110.39%
Shares Short (Jan 30, 2020) 48.4k
Short Ratio (Jan 30, 2020) 40.25
Short % of Float (Jan 30, 2020) 40.08%
Short % of Shares Outstanding (Jan 30, 2020) 40.07%
Shares Short (prior month Dec 30, 2019) 436.22k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 21:20
Last Split Date 3Nov 14, 2018

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 30, 2018
Most Recent Quarter (mrq)Sep 29, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-80.34%
Return on Equity (ttm)-183.48%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)0.00
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)500k
EBITDA -10.56M
Net Income Avi to Common (ttm)-10.13M
Diluted EPS (ttm)-0.91
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)9.74M
Total Cash Per Share (mrq)0.81
Total Debt (mrq)190k
Total Debt/Equity (mrq)1.96
Current Ratio (mrq)8.97
Book Value Per Share (mrq)0.81

Cash Flow Statement

Operating Cash Flow (ttm)-9.14M
Levered Free Cash Flow (ttm)-5.94M